Therapeutic Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Description
Therapeutic Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global therapeutic vaccines market size reached US$ 28.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 51.4 Billion by 2028, exhibiting a growth rate (CAGR) of 10.4% during 2023-2028.
Therapeutic vaccines are a range of biological medications designed to stimulate or trigger the adaptive immune system to prevent disease-causing organisms and infections. They can be modified based on various applications and needs for treating different disorders, including cancer, human immunodeficiency virus (HIV) infections, and Alzheimer’s. Therapeutic vaccines aid in creating antibodies for protecting the body against pathogens, recognizing viruses or cancerous cells, reducing the viral set point in infected patients, and providing better clinical outcomes. Along with this, they are cost-effective, easy to use, and can treat late-stage diseases; thus, it is extensively used in clinical laboratories, hospitals, and vaccination centers for immunization. Currently, they are available in autoimmune, cancer, infectious and neurological disease vaccination types.
Therapeutic Vaccines Market Trends:
The increasing prevalence of various chronic ailments and the growing need for effective biologic medications for specific and targeted responses are primarily driving the therapeutic vaccines market growth. In line with this, the implementation of numerous government initiatives promoting compulsory immunization of individuals during the COVID-19 pandemic and the ongoing funding in biopharmaceutical companies to develop viral recombinants are acting as another growth-inducing factors. Additionally, the extensive utilization of morphogenesis gene therapy with exosome-mediated delivery technology for the advent of patient-specific vaccines to deal with varying cancer types is impelling the market growth. This is further supported by the escalating uptake of genetic engineering, the availability of quick deployment vaccines, and the introduction of faster drug development solutions to improve medicine designs. Apart from this, rapid enhancements in the healthcare sector, fueling consumer awareness regarding the accessibility to several therapeutic drugs, and ongoing research and development (R&D) activities to enhance product effectiveness are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease type, technology and distribution channel.
Breakup by Type:
Antigen Vaccines
Dendritic Cell Vaccine
DNA Vaccine
Tumor Cell Vaccines
Breakup by Disease Type:
Autoimmune Disease Vaccines
Addiction Vaccine
Neurological Disease Vaccine
Infectious Disease Vaccine
Others
Breakup by Technology:
Autologous Vaccines
Allogeneic Vaccine
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agenus Inc., Argos Therapeutics Inc., Bavarian Nordic A/S, Cel-Sci Corporation, CSL Limited, Emergent Biosolutions Inc., GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report
1. What was the size of the global therapeutic vaccines market in 2022?
2. What is the expected growth rate of the global therapeutic vaccines market during 2023-2028?
3. What are the key factors driving the global therapeutic vaccines market?
4. What has been the impact of COVID-19 on the global therapeutic vaccines market?
5. What is the breakup of the global therapeutic vaccines market based on the type?
6. What is the breakup of the global therapeutic vaccines market based on the disease type?
7. What is the breakup of the global therapeutic vaccines market based on the technology?
8. What are the key regions in the global therapeutic vaccines market?
9. Who are the key players/companies in the global therapeutic vaccines market?
The global therapeutic vaccines market size reached US$ 28.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 51.4 Billion by 2028, exhibiting a growth rate (CAGR) of 10.4% during 2023-2028.
Therapeutic vaccines are a range of biological medications designed to stimulate or trigger the adaptive immune system to prevent disease-causing organisms and infections. They can be modified based on various applications and needs for treating different disorders, including cancer, human immunodeficiency virus (HIV) infections, and Alzheimer’s. Therapeutic vaccines aid in creating antibodies for protecting the body against pathogens, recognizing viruses or cancerous cells, reducing the viral set point in infected patients, and providing better clinical outcomes. Along with this, they are cost-effective, easy to use, and can treat late-stage diseases; thus, it is extensively used in clinical laboratories, hospitals, and vaccination centers for immunization. Currently, they are available in autoimmune, cancer, infectious and neurological disease vaccination types.
Therapeutic Vaccines Market Trends:
The increasing prevalence of various chronic ailments and the growing need for effective biologic medications for specific and targeted responses are primarily driving the therapeutic vaccines market growth. In line with this, the implementation of numerous government initiatives promoting compulsory immunization of individuals during the COVID-19 pandemic and the ongoing funding in biopharmaceutical companies to develop viral recombinants are acting as another growth-inducing factors. Additionally, the extensive utilization of morphogenesis gene therapy with exosome-mediated delivery technology for the advent of patient-specific vaccines to deal with varying cancer types is impelling the market growth. This is further supported by the escalating uptake of genetic engineering, the availability of quick deployment vaccines, and the introduction of faster drug development solutions to improve medicine designs. Apart from this, rapid enhancements in the healthcare sector, fueling consumer awareness regarding the accessibility to several therapeutic drugs, and ongoing research and development (R&D) activities to enhance product effectiveness are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease type, technology and distribution channel.
Breakup by Type:
Antigen Vaccines
Dendritic Cell Vaccine
DNA Vaccine
Tumor Cell Vaccines
Breakup by Disease Type:
Autoimmune Disease Vaccines
Addiction Vaccine
Neurological Disease Vaccine
Infectious Disease Vaccine
Others
Breakup by Technology:
Autologous Vaccines
Allogeneic Vaccine
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agenus Inc., Argos Therapeutics Inc., Bavarian Nordic A/S, Cel-Sci Corporation, CSL Limited, Emergent Biosolutions Inc., GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report
1. What was the size of the global therapeutic vaccines market in 2022?
2. What is the expected growth rate of the global therapeutic vaccines market during 2023-2028?
3. What are the key factors driving the global therapeutic vaccines market?
4. What has been the impact of COVID-19 on the global therapeutic vaccines market?
5. What is the breakup of the global therapeutic vaccines market based on the type?
6. What is the breakup of the global therapeutic vaccines market based on the disease type?
7. What is the breakup of the global therapeutic vaccines market based on the technology?
8. What are the key regions in the global therapeutic vaccines market?
9. Who are the key players/companies in the global therapeutic vaccines market?
Table of Contents
145 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Therapeutic Vaccines Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type
- 6.1 Antigen Vaccines
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Dendritic Cell Vaccine
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 DNA Vaccine
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Tumor Cell Vaccines
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 7 Market Breakup by Disease Type
- 7.1 Autoimmune Disease Vaccines
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Addiction Vaccine
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Neurological Disease Vaccine
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Infectious Disease Vaccine
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 8 Market Breakup by Technology
- 8.1 Autologous Vaccines
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Allogeneic Vaccine
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
- 11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Agenus Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Argos Therapeutics Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Bavarian Nordic A/S
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.4 Cel-Sci Corporation
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 CSL Limited
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Emergent Biosolutions Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 GSK plc
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Merck & Co. Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
